Clinical characteristics and prognostic factors of prostate cancer with liver metastases
- 552 Downloads
Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29 %. Eight (29.63 %) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37 %) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.
KeywordsLiver metastases Prostate cancer Predictive factors Survival
The study was supported by NSFC (81071787) and Tianjin Municipal Science and Technology Commission (08JCYBJC10300).
Conflicts of interest
- 4.Na YQ, Sun G, Ye ZQ, Sun YH, Sun ZY. Guideline of Chinese urological disease diagnosis and treatment. Beijing: People’s Health Publishing House; 2009.Google Scholar
- 5.Zheng RS, Zhang SW, Wu LY, Li GL, Ping Z, Hao J. Report of incidence and mortality in China Cancer Registries, 2008. China Cancer. 2012;21:1–12.Google Scholar
- 8.Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, et al. Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). J Clin Oncol. 2012;30(suppl; abstr 4655).Google Scholar